Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achieve Life Sciences Inc ACHV

Healthcare Biotechnology
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of... see more

Recent & Breaking News (NDAQ:ACHV)

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

Canada NewsWire September 13, 2019

Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

Canada NewsWire September 5, 2019

Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

Canada NewsWire September 4, 2019

Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update

Canada NewsWire August 8, 2019

Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019

Canada NewsWire July 30, 2019

Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation

PR Newswire July 23, 2019

Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

PR Newswire June 21, 2019

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

Canada NewsWire June 11, 2019

Achieve Receives $4.2 Million from Exercise of Warrants

Canada NewsWire June 3, 2019

Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline

PR Newswire May 30, 2019

Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update

Canada NewsWire May 15, 2019

Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019

Canada NewsWire May 7, 2019

Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

PR Newswire April 24, 2019

Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019

PR Newswire April 3, 2019

32 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  April 2, 2019

The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Benzinga.com  April 2, 2019

Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

PR Newswire April 2, 2019

Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019

PR Newswire March 18, 2019

Mid-Afternoon Market Update: Catasys Rises After Strong Q4 Results; Ra Medical Systems Shares Plummet

Benzinga.com  March 15, 2019

Mid-Day Market Update: Dow Rises Over 200 Points; Global Eagle Entertainment Shares Fall Following Downbeat Q4 Results

Benzinga.com  March 15, 2019